6515--Radiopharmaceuticals
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) has issued a Justification and Approval (J&A) for an emergency bridge contract to continue radiopharmaceutical services for the Nuclear Medicine Program at the Southeast Louisiana Veterans Health Care System (SLVHCS). This action ensures uninterrupted patient care while a competitive five-year procurement is completed. The contract, valued at $845,129.00, covers services from June 1, 2026, through September 30, 2026.
Purpose & Scope
This contract provides essential radiopharmaceutical support for diagnostic imaging services (scintigraphy), enabling the production of images of organs and tissues using radioactive materials. These services are critical for the diagnosis and treatment of various disease processes, including oncology and cardiac conditions, for veteran patients.
Contract Details
- Type: Emergency Bridge Contract (Justification for Other Than Full and Open Competition)
- Value: $845,129.00
- Period of Performance: June 1, 2026, through September 30, 2026
- Set-Aside: Other Than Full and Open Competition, justified by "Unusual and Compelling Urgency" (41 USC §3304(a)(2)) and "Only One Responsible Source" (41 USC §3304(a)(1)).
- Awardee (Implied Sole Source): RLS USA Inc.
Evaluation & Submission
This document is a justification for a sole-source procurement, not a solicitation. Therefore, there are no proposal submission instructions or evaluation criteria for bidders.
Additional Notes
The current contract for these services expires on May 31, 2026. Market research identified RLS USA Inc. as the sole vendor capable of meeting the specialized radiopharmaceutical requirements due to proximity, range of services, and established regulatory compliance, ensuring timely delivery for clinical effectiveness. The VA plans to conduct further market research for future requirements to enable full and open competition.